BIO-RAD LABORATORIES-A (BIO) Fundamental Analysis & Valuation
NYSE:BIO • US0905722072
Current stock price
281.15 USD
+3.15 (+1.13%)
At close:
281.15 USD
0 (0%)
After Hours:
This BIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BIO Profitability Analysis
1.1 Basic Checks
- In the past year BIO was profitable.
- BIO had a positive operating cash flow in the past year.
- In multiple years BIO reported negative net income over the last 5 years.
- BIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BIO has a better Return On Assets (7.18%) than 85.96% of its industry peers.
- Looking at the Return On Equity, with a value of 10.20%, BIO belongs to the top of the industry, outperforming 80.70% of the companies in the same industry.
- BIO's Return On Invested Capital of 2.02% is fine compared to the rest of the industry. BIO outperforms 63.16% of its industry peers.
- BIO had an Average Return On Invested Capital over the past 3 years of 2.32%. This is significantly below the industry average of 11.38%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROIC | 2.02% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
1.3 Margins
- Looking at the Profit Margin, with a value of 29.42%, BIO belongs to the top of the industry, outperforming 96.49% of the companies in the same industry.
- In the last couple of years the Profit Margin of BIO has declined.
- BIO has a Operating Margin of 10.30%. This is in the better half of the industry: BIO outperforms 70.18% of its industry peers.
- BIO's Operating Margin has declined in the last couple of years.
- The Gross Margin of BIO (52.01%) is better than 61.40% of its industry peers.
- In the last couple of years the Gross Margin of BIO has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% |
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
2. BIO Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
- Compared to 1 year ago, BIO has less shares outstanding
- The number of shares outstanding for BIO has been reduced compared to 5 years ago.
- BIO has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 3.12 indicates that BIO is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.12, BIO is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
- BIO has a debt to FCF ratio of 3.21. This is a good value and a sign of high solvency as BIO would need 3.21 years to pay back of all of its debts.
- The Debt to FCF ratio of BIO (3.21) is better than 82.46% of its industry peers.
- BIO has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
- BIO has a Debt to Equity ratio (0.16) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Altman-Z | 3.12 |
ROIC/WACC0.19
WACC10.53%
2.3 Liquidity
- A Current Ratio of 5.62 indicates that BIO has no problem at all paying its short term obligations.
- BIO has a Current ratio of 5.62. This is amongst the best in the industry. BIO outperforms 82.46% of its industry peers.
- BIO has a Quick Ratio of 4.19. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
- BIO has a Quick ratio of 4.19. This is in the better half of the industry: BIO outperforms 77.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 |
3. BIO Growth Analysis
3.1 Past
- BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
- The Earnings Per Share has been decreasing by -1.19% on average over the past years.
- BIO shows a small growth in Revenue. In the last year, the Revenue has grown by 0.65%.
- The Revenue has been growing slightly by 0.29% on average over the past years.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
3.2 Future
- BIO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.58% yearly.
- The Revenue is expected to grow by 2.54% on average over the next years.
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue Next Year1.88%
Revenue Next 2Y2.54%
Revenue Next 3Y2.56%
Revenue Next 5Y2.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. BIO Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 28.34, BIO can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Earnings ratio of BIO indicates a somewhat cheap valuation: BIO is cheaper than 68.42% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (26.21), we can say BIO is valued inline with the index average.
- BIO is valuated quite expensively with a Price/Forward Earnings ratio of 27.10.
- Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 66.67% of the companies in the same industry.
- BIO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.34 | ||
| Fwd PE | 27.1 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, BIO is valued cheaply inside the industry as 82.46% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.26 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO does not grow enough to justify the current Price/Earnings ratio.
- BIO has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)6.2
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y7.11%
5. BIO Dividend Analysis
5.1 Amount
- No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIO Fundamentals: All Metrics, Ratios and Statistics
281.15
+3.15 (+1.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-30 2026-04-30/amc
Inst Owners90.44%
Inst Owner Change0%
Ins Owners8.17%
Ins Owner Change0%
Market Cap7.59B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target341.7 (21.54%)
Short Float %5.5%
Short Ratio3.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)0%
PT rev (3m)-5.63%
EPS NQ rev (1m)-8.74%
EPS NQ rev (3m)-28.16%
EPS NY rev (1m)0%
EPS NY rev (3m)0.7%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)-2.7%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)-0.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.34 | ||
| Fwd PE | 27.1 | ||
| P/S | 2.94 | ||
| P/FCF | 20.26 | ||
| P/OCF | 14.26 | ||
| P/B | 1.02 | ||
| P/tB | 1.13 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.53%
EPS(NY)10.37
Fwd EY3.69%
FCF(TTM)13.88
FCFY4.94%
OCF(TTM)19.72
OCFY7.01%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)6.2
PEG (5Y)N/A
Graham Number248.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROCE | 2.65% | ||
| ROIC | 2.02% | ||
| ROICexc | 2.38% | ||
| ROICexgc | 2.62% | ||
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% | ||
| FCFM | 14.5% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.1% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 49.3% | ||
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 | ||
| Altman-Z | 3.12 |
F-Score5
WACC10.53%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year1.88%
Revenue Next 2Y2.54%
Revenue Next 3Y2.56%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.85%
EBIT Next 3Y17.21%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%
BIO-RAD LABORATORIES-A / BIO Fundamental Analysis FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 5 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 4 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Fairly Valued.
How profitable is BIO-RAD LABORATORIES-A (BIO) stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 6 / 10.
What is the valuation of BIO-RAD LABORATORIES-A based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES-A (BIO) is 28.34 and the Price/Book (PB) ratio is 1.02.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 4.57% in the next year.